Global Neurofeedback Systems Market Size, Share & Forecast, By Product Type, Application & End User, 2026-2031

The Global Neurofeedback Systems Market was valued at USD 1.45 billion in 2025. The estimate includes clinical and consumer neurofeedback devices, software subscriptions, protocol platforms, implementation, training and directly attributable technical services. It excludes general EEG diagnostic revenue unrelated to neurofeedback, broader neuromodulation systems, implanted brain-computer interfaces and ordinary clinical consultation fees. North America represented approximately 40% of demand, while devices accounted for about 70% of revenue. Portable configurations represented nearly half of global market activity.

The market is forecast to reach approximately USD 2.22 billion by 2031, expanding at a 7.35% CAGR during 2026-2031. Growth is expected to be supported by clinician-supervised home delivery, portable EEG adoption, expanding behavioral-health demand and higher software content per deployment. Annualized system-equivalent volume is projected to grow faster than value because headset and sensor costs continue declining. Vendors that combine validated clinical workflows with remote monitoring and recurring platform revenue should outperform hardware-only competitors.

Profit pools are expected to move toward software platforms, protocol libraries, practitioner dashboards, remote supervision and outcome analytics. Devices represented approximately 70% of market revenue in 2025, but software and services are projected to grow faster at about 7.68% annually. Portable hardware is becoming more standardized, placing downward pressure on ASPs. In contrast, compliant data platforms can generate recurring revenue, improve practitioner retention and support differentiated clinical workflows. Vendors with high software attachment and low customer churn should therefore command stronger margins.

The principal constraint is uneven reimbursement combined with heterogeneous clinical evidence. Medicare coverage for biofeedback remains limited to narrow indications, while several psychiatric neurofeedback services are commonly paid by clinics or consumers. Protocol differences in frequency bands, electrode placement, session duration and outcome measurement also complicate payer review. Treatment can require 10 to fewer than 40 sessions, creating affordability and adherence barriers. Evidence standardization and outcome registries are therefore essential for wider institutional procurement and coverage.

The United States offers the strongest commercial position among selected peer countries, with an estimated USD 435 million market in 2025. It benefits from high healthcare expenditure, established behavioral-health networks, major neuroscience research institutions and a defined FDA Class II biofeedback-device pathway. Its 7.57% projected CAGR exceeds Germany and Canada, although Japan may grow slightly faster from a smaller base. The United States also has substantial diagnosed ADHD populations across both children and adults, supporting recurring clinical demand.

The largest demand factor is the scale of neurological and mental-health need combined with limited access to specialist care. More than 3 billion people had a neurological condition in 2021, while 1.1 billion people lived with a mental disorder. Neurofeedback will not address every condition, but this need base supports research and adoption across ADHD, anxiety, stress, sleep, rehabilitation and performance applications. Portable systems and remote clinical oversight can extend access where specialist capacity is limited, provided signal quality and patient supervision remain reliable.